|0.2079 0.004 (1.76%)||12-01 16:00|
|Targets||6-month :||0.29||1-year :||0.33|
|Resists||First :||0.25||Second :||0.28|
|Supports||First :||0.19||Second :||0.16|
|MAs||MA(5) :||0.2||MA(20) :||0.23|
|MA(100) :||0.26||MA(250) :||0.73|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||12.9||D(3) :||9.6|
|52-week||High :||1.97||Low :||0.16|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PIRS ] has closed above bottom band by 29.7%. Bollinger Bands are 29.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||0.21 - 0.21||0.21 - 0.21|
|Low:||0.2 - 0.2||0.2 - 0.2|
|Close:||0.21 - 0.21||0.21 - 0.21|
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Wed, 08 Nov 2023
North American Morning Briefing: Stock Futures -2- - Morningstar
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||99 (M)|
|Shares Float||61 (M)|
|Held by Insiders||14.9 (%)|
|Held by Institutions||67.9 (%)|
|Shares Short||186 (K)|
|Shares Short P.Month||573 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0.31|
|Profit Margin||-59.3 %|
|Operating Margin||15.8 %|
|Return on Assets (ttm)||-17.3 %|
|Return on Equity (ttm)||-84.7 %|
|Qtrly Rev. Growth||263.5 %|
|Gross Profit (p.s.)||-0.28|
|Sales Per Share||0.47|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-47 (M)|
|Levered Free Cash Flow||-29 (M)|
|Price to Book value||0.67|
|Price to Sales||0.43|
|Price to Cash Flow||-0.44|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|